Protein Chemistry

PPT 8

Quiz ChatGPT conversation

🩸 Haemophilia – Full Conceptual Overview

🧬 What is haemophilia?

A bleeding disorder where blood cannot clot properly
Can be:
- Inherited (most common, X-linked)
- Acquired (rare)
Leads to:
- Internal bleeding
- Joint damage
- Pain, disability, even death if untreated

👉 Key takeaway: Clotting is not absent — it’s inefficient and delayed, which is enough to cause major problems.

👶 Clinical case (Page 2)

A 9-month-old boy:

Bruising without trauma
Large hematoma
No family history

🔍 Interpretation

Classic early haemophilia presentation
Often misinterpreted as:
- Child abuse
Key clue:
- Unusual bruising + injections causing bleeding

👉 Important concept: Haemophilia can appear even without family history (new mutations).

🧪 Blood testing (Page 3)

From the lab table:

APTT ↑ (prolonged) → intrinsic pathway problem
Factor VIII very low (~0.01)
Factor IX normal

🧠 Interpretation:

This is Haemophilia A (Factor VIII deficiency)

👉 Rule:

Intrinsic pathway issue = APTT prolonged
PT normal → extrinsic pathway intact

📊 Severity classification (Page 4)

Severity	Factor activity	Clinical picture
Mild	5–40%	Bleeding after trauma
Moderate	1–5%	Occasional bleeding
Severe	<1%	Spontaneous bleeding

📉 Graph explanation (page 4)

Y-axis: clot activity
X-axis: time
Severe haemophilia → very slow/low clot formation
Mild → delayed but functional

👉 Insight: Even small reductions in factor levels → nonlinear drop in clotting efficiency

🌍 Epidemiology (Page 5)

Haemophilia A:
- ~1 in 5,000 males
- 80–85% of cases
Haemophilia B:
- ~1 in 30,000 males

👉 Reason:

X-linked → mostly affects males

🦴 Joint damage (Pages 6–8)

📸 Image explanation

Swollen knees, elbows, ankles
Deformed joints
Reduced mobility

🧠 Mechanism:

Repeated bleeding →

Blood enters joint
Inflammation
Cartilage damage
Chronic degeneration

🔁 Vicious cycle (Page 9)

Diagram meaning:

Bleed → inflammation → tissue destruction → poor healing → new bleed

👉 Key insight:

Haemophilia is not just bleeding
It becomes a self-reinforcing degenerative disease

🧑‍⚕️ Quality of life (Page 10)

Reduced mobility
Pain
Social/psychological impact

👉 Important: Modern therapy aims not just to stop bleeding, but to restore normal life

🧪 Treatment evolution (Page 11–12)

Timeline:

❌ Supportive care only
🧊 Plasma / cryoprecipitate
⚠️ HIV contamination crisis (1980s)
🧬 Recombinant factors
💉 Long-acting therapies
🧠 New mechanisms (bispecific antibodies)
🧬 Gene therapy

⚠️ Ryan White case (Page 12)

Haemophilia patient infected with HIV from contaminated blood products
Highlighted safety issues in early treatments

⚙️ Coagulation Cascade (Pages 13–14, 26)

🧠 Big picture

Clotting = enzyme cascade amplification system

Two pathways:

Intrinsic (contact activation)
Extrinsic (tissue factor)

→ Both converge to:

Common pathway:

FX → FXa
Prothrombin → Thrombin
Fibrinogen → Fibrin clot

🔬 What goes wrong in haemophilia?

Haemophilia A → missing FVIII
Haemophilia B → missing FIX

Critical step:

FVIII + FIXa → activate FX

👉 Without FVIII:

This step is inefficient → no thrombin burst

🔥 Cell-based model (Page 26)

Phases:

Initiation
- Small thrombin produced
Propagation
- Massive amplification (“thrombin burst”)

👉 Haemophilia problem:

Initiation OK
Propagation FAILS

💊 Modern treatment: FVIII mimetics (Mim8)

🧬 Concept (Pages 16–18)

Instead of replacing FVIII:

👉 Mim8 = bispecific antibody

One arm binds FIXa
One arm binds FX

🧠 Mechanism:

Acts as a bridge → mimics FVIII function

📊 Mechanism diagram (Page 18)

Key points:

Works at bleeding site
Weak binding in circulation → avoids clotting everywhere
Strong local activation → efficient clotting

👉 Insight: Spatial control = safety

⚖️ Optimization challenge (Pages 19–21)

Problem:

Too strong binding → thrombosis
Too weak → ineffective

Solution:

Tune:
- Affinity (KD)
- Potency

🧪 Graph interpretation (Pages 22–23)

Page 22:

Mutagenesis → increasing FIXa stimulation
Up to 1000× improvement

Page 23:

Mim8 vs emicizumab:
- Much higher stimulation of FX activation

👉 Key concept: Enzyme activation > simple binding

💊 Oral therapy frontier (Inno8)

🚀 Why oral is hard (Page 25)

Proteins:

Degraded in stomach
Poor absorption

Constraints:

Stability
Size
Pharmacokinetics

🐪 Solution: VHH antibodies (camelid) (Page 28)

Smaller than IgG
More stable
Easier to engineer

🧪 Discovery workflow (Page 28)

Identify binding domains
Create libraries
Screen activity
Optimize best candidates

👉 Classic protein engineering pipeline

⚙️ Mechanism (Page 31)

Inno8:

Binds FIXa + FX
Promotes FX → FXa
Releases product quickly

👉 Important: Avoids product inhibition

📊 Optimization graphs (Page 29–30)

Page 29:

Scatter plot → activity vs variants
Shows:
- Large diversity
- Selection of best candidates

Page 30:

Half-life optimization via:
- Fatty acid chains → albumin binding

👉 Insight: Binding to albumin = longer circulation

💊 SNAC absorption (Page 33)

Mechanism:

Enhances stomach absorption
Creates local pH environment
Enables transcellular transport

👉 Used in drugs like semaglutide

⏳ Half-life data (Pages 34–35)

~115 hours in dogs

Graph meaning:

Oral dosing becomes more stable over time
Reduced variability after repeated dosing

🧠 Final conclusions (Page 36)

Inno8:

High potency
Long half-life
Oral bioavailability

👉 Potential breakthrough: First oral therapy for haemophilia A

🔑 Key Takeaways

🧠 Disease

Haemophilia = failure of amplification in coagulation
Leads to chronic joint damage

⚙️ Mechanism

Missing FVIII or FIX → no thrombin burst

💊 Treatment evolution

Replacement → engineered antibodies → oral therapies

🚀 Innovation trend

Shift from:
- “Replace missing protein” → “Rewire the system”

Quiz

Score: 0/31 (0%)

Q0. Which factor deficiency defines haemophilia A?

Factor IX deficiency

Factor VIII deficiency

Factor X deficiency

Factor XI deficiency

Q1. Which factor deficiency defines haemophilia B?

Factor VIII deficiency

Factor IX deficiency

Factor VII deficiency

Factor XIII deficiency

Q2. In the Danish case, why was haemophilia clinically suspected despite no family history?

The child had repeated infections and poor growth

The child had unexplained bruising and a large haematoma without clear trauma

The child had severe nosebleeds after every meal

The child had low platelet count after vaccination

Q3. Which laboratory pattern is most consistent with haemophilia A or B?

Prolonged APTT with reduced FVIII or FIX activity

Prolonged PT with reduced fibrinogen

Low platelet count with normal coagulation factor activity

High thrombin generation with reduced bleeding tendency

Q4. What factor activity level is generally associated with severe haemophilia?

More than 50% activity

5-50% activity

1-5% activity

Less than 1% activity

Q5. Why is joint damage described as a major clinical manifestation of haemophilia?

Because clotting factors directly digest cartilage

Because repeated bleeding into joints causes inflammation, destruction, poor healing, and further bleeding

Because haemophilia primarily blocks bone mineralization

Because haemophilia causes autoimmune attack against synovial tissue in every patient

Q6. What does inhibitor formation mean in the context of haemophilia treatment?

The patient produces antibodies that neutralize or reduce the effect of replacement clotting factors

The patient stops producing platelets

The treatment permanently cures the genetic defect

The liver produces too much Factor VIII

Q7. Which statement best summarizes the historical development of haemophilia treatment?

Treatment moved directly from gene therapy to plasma-derived products

Treatment progressed from supportive care and plasma products to recombinant factors, long-acting products, new modes of action, and gene therapy

Treatment has always relied only on oral tablets

Treatment stopped developing after cryoprecipitate was introduced

Q8. What was one major tragedy associated with early plasma-derived haemophilia treatments?

Excessive insulin contamination

Blood-borne pathogen transmission, including HIV

Complete failure of all recombinant therapies

Loss of all Factor IX products

Q9. In the coagulation cascade, why are FVIIIa and FIXa important for thrombin burst generation?

They directly convert fibrin into fibrinogen

They form a functional complex that efficiently activates FX to FXa

They remove tissue factor from the endothelium

They inhibit platelet activation

Q10. What is the basic therapeutic concept behind Mim8?

It replaces platelets in the blood

It acts as a FVIIIa-mimetic bispecific antibody that bridges FIXa and FX

It blocks Factor X activation completely

It degrades inhibitors against Factor VIII

Q11. Why was the affinity of the anti-FX arm of Mim8 intentionally lowered during optimization?

To eliminate all FX binding

To reduce systemic coagulation risk, target-mediated clearance, and hook effect while maintaining activity

To increase platelet destruction

To make the molecule bind only to fibrinogen

Q12. What does an increased KD value indicate in the context of Mim8 anti-FX optimization?

Higher affinity binding

Lower affinity binding

No change in binding

Complete enzymatic inhibition

Q13. What was the purpose of optimizing the anti-FIXa arm of Mim8?

To reduce FIXa binding to zero

To increase the stimulatory effect on FIXa proteolytic activity

To prevent FX activation entirely

To convert FIXa into FVIII

Q14. What is the main aspiration of the Inno8 project?

To develop an oral next-generation FVIII mimetic drug for prophylactic treatment of haemophilia A

To develop a vaccine against haemophilia B

To replace all clotting factors with platelets

To create a diagnostic test for bruising disorders only

Q15. True or false: Haemophilia can lead to severe joint damage because untreated bleeds can trigger repeated inflammation and tissue destruction.

True

False

Q16. True or false: Haemophilia A represents the minority of haemophilia cases, while haemophilia B represents about 80-85%.

True

False

Q17. True or false: Severe haemophilia is associated with spontaneous bleeding and very low factor activity.

True

False

Q18. True or false: Inhibitor formation can make treatment more difficult because antibodies may neutralize traditional clotting factor replacement therapies.

True

False

Q19. True or false: The coagulation cascade is useful because it amplifies a small initiating signal into a large thrombin burst and fibrin clot.

True

False

Q20. True or false: In haemophilia A, the main defect is usually in the extrinsic tissue factor pathway before any thrombin can be made.

True

False

Q21. True or false: Mim8 is designed to replace the bridging function of FVIIIa by bringing FIXa and FX together.

True

False

Q22. True or false: For Mim8, very high affinity binding everywhere in circulation is always desirable because it guarantees stronger clotting.

True

False

Q23. True or false: Mutagenesis was used to optimize both binding and functional properties of FVIIIa-mimetic molecules.

True

False

Q24. True or false: Inno8 is based on camelid VHH domains rather than a full conventional IgG antibody structure.

True

False

Q25. True or false: The anti-FX VHH in Inno8 binds the FX activation peptide and facilitates immediate FXa release after activation.

True

False

Q26. True or false: Albumin-binding protraction technology was used to shorten Inno8 plasma half-life so the drug disappears rapidly.

True

False

Q27. True or false: SNAC is an absorption enhancer used to support oral delivery of peptide or protein-like therapeutics through stomach absorption.

True

False

Q28. True or false: The document states that in vitro thrombin generation results from FVIIIa mimetics always translate directly into clinical efficacy.

True

False

Q29. True or false: Inno8 showed a terminal plasma half-life of 115 hours in beagle dogs after intravenous dosing.

True

False

Q30. True or false: The final conclusion of the document is that Inno8 may have potential as the first oral treatment for severe haemophilia A.

True

False